The short version of thymosin alpha 1 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-03-04. Anything still debated is marked as such rather than presented as settled.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 3,108 Da | Consistent with a 28-residue acetylated peptide |
| Residue count | 28 | Corresponds to the amino terminal region of prothymosin alpha |
| Appearance of dry powder | White to off-white solid | Slight variation between lots is normal |
| Solubility class | Freely soluble in water | Low solubility in most organic solvents |
| Common synonyms | Thymosin alpha 1, T alpha 1 | The numeral reflects an early fraction numbering scheme |
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Methylphenidate is a psychostimulant drug that is often used in the treatment of ADHD and narcolepsy and occasionally to treat obesity in combination with diet restraints and exercise. Its effects at therapeutic doses include increased focus, increased alertness, decreased appetite, decreased need for sleep and decreased impulsivity. Methylphenidate is not usually used recreationally, but when it is used, its effects are similar to those of amphetamines. Methylphenidate acts as a norepinephrine–dopamine reuptake inhibitor (NDRI), by blocking the norepinephrine transporter (NET) and the dopamine transporter (DAT). Methylphenidate has a higher affinity for the dopamine transporter than for the norepinephrine transporter, and so its effects are mainly due to elevated dopamine levels caused by the inhibited reuptake of dopamine, however increased norepinephrine levels also contribute to various of the effects caused by the drug. Methylphenidate is sold under a number of brand names including Ritalin. Other versions include the long lasting tablet Concerta and the long lasting transdermal patch Daytrana.
In 1966, Dayhoff pioneered the use of computers in comparing protein sequences and reconstructing their evolutionary histories from sequence alignments. To perform this work, she created the single-letter amino acid code to minimize the data file size for each sequence. This work, co-authored with Richard Eck, was the first application of computers to infer phylogenies from molecular sequences. It was the first reconstruction of a phylogeny (evolutionary tree) by computers from molecular sequences using a maximum parsimony method. In later years, she applied these methods to study a number of molecular relationships, such as the catalytic chain and bovine cyclic AMP-dependent protein kinase and the src gene product of Rous avian and Moloney murine sarcoma viruses; antithrombin-III, alpha-antitrypsin, and ovalbumin; epidermal growth factor and the light chain of coagulation factor X; and apolipoproteins A-I, A-II, C-I and C-III. Based on this work, Dayhoff and her coworkers developed a set of substitution matrices called the PAM (Accepted Point Mutation), MDM (Mutation Data Matrix), or Dayhoff Matrix. They are derived from global alignments of closely related protein sequences. The identification number included with the matrix (ex. PAM40, PAM100) refers to the evolutionary distance; greater numbers correspond to greater distances. Matrices using greater evolutionary distances are extrapolated from those used for lesser ones.
Caldwell, Donald and Richard Muller. The Luftwaffe over Germany – Defense of the Reich. St. Paul, Minnesota: Greenhill books, MBI Publishing, 2007. ISBN 978-185367-712-0. Carson, Leonard "Kit." Pursue & Destroy. Granada Hills, California: Sentry Books Inc., 1978. ISBN 0-913194-05-0. Carter, Dustin W. and Birch J. Matthews.Mustang: The Racing Thoroughbred. West Chester, Pennsylvania: Schiffer Publishing Company, 1992. ISBN 978-0-88740-391-0. Cleaver, Tom (April–July 1982). "Return of the Razorbacks". Air Enthusiast. No. 18. pp. 26–31. ISSN 0143-5450. Craven, Wesley; Cate, James (1949). The Army Air Forces in World War II, Volume Two: Europe, Torch to Pointblank, August 1942 to December 1943. Chicago: University of Chicago. Darling, Kev. P-51 Mustang (Combat Legend). Shrewsbury, UK: Airlife, 2002. ISBN 1-84037-357-1. Davis, Larry. P-51 Mustang. Carrollton, Texas: Squadron/Signal Publications, Inc., 1995. ISBN 0-89747-350-7. Dean, Francis H. America's Hundred Thousand. Atglen, Pennsylvania: Schiffer Publishing Ltd., 1997. ISBN 0-7643-0072-5. Delve, Ken. The Mustang Story. London: Cassell & Co., 1999. ISBN 1-85409-259-6. Delve, Ken. The Source Book of the RAF. Shrewsbury, Shropshire, UK: Airlife Publishing, 1994. ISBN 1-85310-451-5. Dienst, John and Dan Hagedorn. North American F-51 Mustangs in Latin American Air Force Service. London: Aerofax, 1985. ISBN 0-942548-33-7. Donald, David, ed. Encyclopedia of World Aircraft. Etobicoke, Ontario: Prospero, 1997. ISBN 1-85605-375-X. Dorr, Robert F. P-51 Mustang (Warbird History). St.
The clearance rate, or the rate at which the carrier protein is broken down, for GHBP alone is much faster than when it is bound to its ligand. Additionally, current literature provides evidence that the carrier-protein prolongs the half-life of growth hormone through its binding with the ligand. One purpose of GHBP can be inferred: to maintain the level of GH in the blood, as roughly half of its concentration is complexed with GHBP. Yet this could be confounded by the fact that GH binding to GHBP prevents the ligand from binding to GHR and ultimately proteolytic activity. Another function is that GHBP displays competitive inhibition for GH against the GHR receptor. Studies elucidate another aspect of GHBP physiological role: The proteolytic cleavage activity that forms GHBP ultimately regulates GHR production in humans as well as rats. If there is low GHBP concentration then there are high levels of GHR expression. Conversely, high levels of GHBP protein show negative correlation with levels of growth hormone receptor expression.
Sources: en.wikipedia.org
Stephen H. White was an American Biophysicist, academic, and author. He was a Professor Emeritus of Physiology and Biophysics at the University of California, Irvine School of Medicine. White published over 350 papers, was cited over 30,000 times, and had a Google Scholar H-index of 84. He focused his research on structure and folding of membrane proteins, with particular attention on protein structure prediction, peptide–bilayer interactions, cell membrane biophysics, structure of membranes and lipid bilayers, and antimicrobial peptides. He was awarded the 2014 Carl Brändén Award for his contributions to the field of membrane protein folding. He authored several book chapters and two books entitled, Membrane Protein Structure: Experimental Approaches and Cell Boundaries: How Membranes and Their Proteins Work. White was a Fellow of the American Association for the Advancement of Science, Neutron Scattering Society of America, and Biophysical Society, where he also served as President (1996-1997). He served on numerous advisory boards of several professional organizations, including NIH, NSF, Department of Energy, and European Science Foundation.
=== Indiana === Indiana passed the first sterilization law in the United States, the 1907 Indiana Eugenics Law. It was proposed as a part of the Progressive-era wave in which public health advocacy began coming to light.
=== Steps === Lyse cells and prepare sample for immunoprecipitation. Pre-clear the sample by passing the sample over beads alone or bound to an irrelevant antibody to soak up any proteins that non-specifically bind to the IP components. Incubate solution with antibody against the protein of interest. Antibody can be attached to solid support before this step (direct method) or after this step (indirect method). Continue the incubation to allow antibody-antigen complexes to form. Precipitate the complex of interest, removing it from bulk solution. Wash precipitated complex several times. Spin each time between washes when using agarose beads or place tube on magnet when using superparamagnetic beads and then remove the supernatant. After the final wash, remove as much supernatant as possible. Elute proteins from the solid support using low-pH or SDS sample loading buffer. Analyze complexes or antigens of interest. This can be done in a variety of ways: SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) followed by gel staining. SDS-PAGE followed by: gel staining, cutting out individual stained protein bands, and sequencing the proteins in the bands by matrix-assisted laser desorption/ionization (MALDI) mass spectrometry. Transfer and Western blot using another antibody for proteins that were interacting with the antigen, followed by detection using a chemiluminescent or fluorescent secondary antibody.
De Duve won the Francqui Prize for Biological and Medical Sciences in 1960, and the Nobel Prize for Physiology or Medicine in 1974. King Baudouin of Belgium honoured him to Viscount in 1989. He was the recipient of the Gairdner Foundation International Award in 1967, and the Dr H.P. Heineken Prize for Biochemistry and Biophysics in 1973 from the Royal Netherlands Academy of Arts and Sciences. He was elected a foreign associate of the National Academy of Sciences (United States) in 1975. He won the Harden Medal of the Biochemical Society of Great Britain in 1978; the Theobald Smith Award from the Albany Medical College in 1981; the Jimenez Diaz Award in 1985; the Innovators of Biochemistry Award from Medical College of Virginia in 1986; and the E.B. Wilson Medal in 1989. He was also a member of the Royal Academies of Medicine and the Royal Academy of Sciences, Arts, and of Literature of Belgium; the Pontifical Academy of Sciences of the Vatican; the American Academy of Arts and Sciences; the French National Academy of Medicine; the Academy of Sciences of Paris; the Deutsche Akademie der Naturforscher Leopoldina; the American Philosophical Society. He was elected a Foreign Member of the Royal Society (ForMemRS) in 1988. In addition, he received honorary doctorates from eighteen universities around the world.
=== Arms === The PLA maintains four arms (Chinese: 兵种): the Aerospace Force, the Cyberspace Force, the Information Support Force, and the Joint Logistics Support Force. The four-arm system was established on 19 April 2024.
Sources: en.wikipedia.org
CaCO3·MgCO3 → MgO·CaO + 2 CO2 Reduction occurs at high temperatures with silicon. A ferrosilicon alloy is used rather than pure silicon as it is more economical. The iron component has no bearing on the reaction, having the simplified equation:
== Mechanism == There are two common IRIS scenarios. The first is the "unmasking" of an occult opportunistic infection. The second is the "paradoxical" symptomatic relapse of a prior infection despite microbiologic treatment success. Often in paradoxical IRIS, microbiologic cultures are sterile. In either scenario, there is hypothesized reconstitution of antigen-specific T cell-mediated immunity with activation of the immune system against persisting antigen, whether present as intact organisms, dead organisms, or debris.
=== Detailed expression of Thy-1 === In mice, Thy-1 is also found on thymocytes, peripheral T cells, myoblasts, epidermal cells, and keratinocytes. It is one of the "pan T cell markers"(of mice) like CD2, CD5 and CD28. In humans, Thy-1 is also expressed by endothelial cells, smooth muscle cells, a subset of CD34+ bone marrow cells, and umbilical cord blood-, cardiac fibroblasts, and fetal liver-derived hemopoietic cells. Thy-1 is present on a fraction of brain cells and a fraction of fibroblasts of most vertebrate species studied. Nervous tissue: Thy-1 expression in the nervous system is predominantly neuronal, but some glial cells also express Thy-1 especially at later stages of their differentiation. One study compared Thy-1 expression in four human neuronal cell lines, two neuroglial cell lines, and fresh tumor cells of neuronal origin and found three of the four neuronal cell lines, all of the neuroglial cell lines, and 80% of the tumors to be strongly positive for Thy-1. Brain part specific ELISA reports are available which show highest concentrations of Thy-1 protein in the striatum and hippocampus, followed by the neocortex, cerebellum, spinal cord, and the retina and optic nerve. Thy-1 promoter has often been assumed to be "brain specific". "Neuron specific" mouse Thy-1 promoter has been used to drive "brain specific" forced expression of proteins e.g. mutated Amyloid precursor protein(APP) as transgenic animal models of Alzheimer's disease. Thy-1 expression in the brain is developmentally regulated.
USAF Pararescue combat medics in Afghanistan used fentanyl lozenges in the form of lollipops on combat casualties from IED blasts and other trauma. The stick is taped to a finger and the lozenge put in the cheek of the person. When enough fentanyl has been absorbed, the (sedated) person generally lets the lollipop fall from the mouth, indicating sufficient analgesia and somewhat reducing the likelihood of overdose and associated risks.
This represents the multi-compartment model with a number of curves that express complicated equations in order to obtain an overall curve. A number of computer programs have been developed to plot these equations. The most complex PK models (called PBPK models) rely on the use of physiological information to ease development and validation. The graph for the non-linear relationship between the various factors is represented by a curve; the relationships between the factors can then be found by calculating the dimensions of different areas under the curve. The models used in non-linear pharmacokinetics are largely based on Michaelis–Menten kinetics. A reaction's factors of non-linearity include the following:
Sources: en.wikipedia.org
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.
Thymosin alpha-1 is a single defined 28-residue peptide, while the broader family includes unrelated peptides such as thymosin beta-4. The shared name reflects historical isolation from thymus tissue rather than a common structure. Confusion between the two is common in older literature.
No single pathway fully accounts for its reported effects. Several studies describe interaction with innate immune receptors and downstream cytokine changes, but the complete picture is not settled. Open questions remain about which effects occur at physiological concentrations.